- Trials with a EudraCT protocol (23)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
23 result(s) found for: Double stranded DNA.
Displaying page 1 of 2.
EudraCT Number: 2013-000634-35 | Sponsor Protocol Number: CB-17-01/08 | Start Date*: 2013-05-11 | |||||||||||
Sponsor Name:Cosmo Technologies Ltd. | |||||||||||||
Full Title: Effect of oral administration of Methylene Blue MMX® tablets on double-stranded DNA damage assessed by γH2AX analysis of colon biopsy samples | |||||||||||||
Medical condition: Out-patients of both sexes scheduled for a screening or surveillance colonoscopy and identified as having the clinical requirement for a second colonoscopy within 2 weeks of the initial colonoscopy. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002984-14 | Sponsor Protocol Number: AC-064A201 | Start Date*: 2015-06-05 |
Sponsor Name:ACTELION Pharmaceuticals Ltd | ||
Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-response study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ACT-334441 in subjects with sy... | ||
Medical condition: Systemic lupus erythematosus | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BG (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-002767-95 | Sponsor Protocol Number: 12/0161 | Start Date*: 2013-06-17 | |||||||||||
Sponsor Name:University College London | |||||||||||||
Full Title: Long term antibody response to CMV gB vaccine in patients requiring liver or renal transplant. A Phase II open, single-site study, in participants who received CMV gB vaccine or placebo in previous... | |||||||||||||
Medical condition: Cytomegalovirus. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002716-26 | Sponsor Protocol Number: C87088 | Start Date*: 2008-01-22 | |||||||||||
Sponsor Name:UCB Celltech | |||||||||||||
Full Title: A phase IIIb, multinational, open-label, follow-on trial to C87085 designed to assess the long-term safety of certolizumab pegol, a pegylated Fab' fragment of a humanized anti TNF alpha monoclonal ... | |||||||||||||
Medical condition: Crohn's disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) FI (Prematurely Ended) HU (Completed) LV (Completed) EE (Completed) IT (Completed) CZ (Completed) AT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-005766-34 | Sponsor Protocol Number: ABI-H0731-204 | Start Date*: 2021-07-22 | |||||||||||
Sponsor Name:Assembly Biosciences, Inc. | |||||||||||||
Full Title: A Randomized Phase 2a, Multicenter, Open-Label, Multiple-Cohort Study Evaluating Regimens Containing Vebicorvir in Subjects with Chronic Hepatitis B Virus Infection | |||||||||||||
Medical condition: Chronic Hepatitis B Virus Infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-004045-81 | Sponsor Protocol Number: AUR-VCS-2016-01 | Start Date*: 2017-05-16 | |||||||||||
Sponsor Name:Aurinia Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Controlled Double-blind Study Comparing the Efficacy and Safety of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Achieving Renal Response in Subjects with Active Lupus Ne... | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Completed) ES (Completed) NL (Completed) PL (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2016-004046-28 | Sponsor Protocol Number: AUR-VCS-2016-02 | Start Date*: 2018-05-23 | |||||||||||
Sponsor Name:Aurinia Pharmaceuticals, Inc. | |||||||||||||
Full Title: A Randomized, Controlled, Double-blind, Continuation Study Comparing the Long-term Safety and Efficacy of Orelvo (voclosporin) (23.7 mg Twice Daily) with Placebo in Subjects with Lupus Nephritis | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) BG (Completed) HR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-023396-25 | Sponsor Protocol Number: SM101-201-sle-10 | Start Date*: 2011-09-22 | |||||||||||
Sponsor Name:SuppreMol GmbH | |||||||||||||
Full Title: Phase IIa, 2:2:1 randomised, double-blind, placebo-controlled, parallel group, multi-centre clinical trial to investigate the safety, efficacy and pharmacokinetics of recombinant human soluble F... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) DE (Completed) CZ (Completed) PL (Completed) NL (Completed) ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-001039-11 | Sponsor Protocol Number: GA30044 | Start Date*: 2016-11-16 | |||||||||||
Sponsor Name:Genentech, Inc. | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF THE SAFETY AND EFFICACY OF GDC-0853 IN PATIENTS WITH MODERATE TO SEVERE ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) PT (Completed) ES (Completed) BG (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2018-004175-12 | Sponsor Protocol Number: B7931028 | Start Date*: 2019-10-01 | |||||||||||
Sponsor Name:Pfizer Inc. | |||||||||||||
Full Title: A PHASE 2B, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, MULTICENTER, DOSE RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY PROFILE OF PF-06700841 IN PARTICIPANTS WITH ACTIVE SYSTEMIC LUPUS ERYTH... | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) HU (Completed) GB (GB - no longer in EU/EEA) CZ (Completed) RO (Completed) BG (Completed) PT (Completed) DE (Completed) PL (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2022-002764-79 | Sponsor Protocol Number: RESCUE | Start Date*: 2023-04-13 | |||||||||||
Sponsor Name:Fundació Clínic per a la Recerca Biomèdica | |||||||||||||
Full Title: Diagnostic yield of Endoscopic aspiration of duodenopancreatic juice after secretin stimulation (ADPJ-secr-) vs endoscopic ultrasound-guided fine needle aspiration (EUS-FNA) for molecular analysis ... | |||||||||||||
Medical condition: Intraductal papillary mucinous intraductal neoplasia | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-001508-12 | Sponsor Protocol Number: CVAY736X2208 | Start Date*: 2018-11-02 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: A placebo-controlled, patient and investigator blinded, randomized parallel cohort study to assess pharmacodynamics, pharmacokinetics, safety, tolerability and preliminary clinical efficacy of VA... | |||||||||||||
Medical condition: Systemic lupus erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) DE (Completed) ES (Completed) FR (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-022099-29 | Sponsor Protocol Number: H9B-MC-BCDS | Start Date*: 2011-07-04 | |||||||||||
Sponsor Name:Eli Lilly and Company | |||||||||||||
Full Title: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE) (ILLUMIN... | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) AT (Completed) IT (Completed) BG (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000097-29 | Sponsor Protocol Number: WA42985 | Start Date*: 2021-09-23 | |||||||||||
Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE II, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF OBINUTUZUMAB IN ADOLESCENT PATIENTS WITH ACTIVE CLASS III OR IV... | |||||||||||||
Medical condition: Lupus Nephritis (LN) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Trial now transitioned) PL (Trial now transitioned) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-005807-37 | Sponsor Protocol Number: AUR-VCS-2020-03 | Start Date*: 2022-04-08 | |||||||||||
Sponsor Name:Aurinia Pharmaceuticals Inc. | |||||||||||||
Full Title: A Double-Blind, Placebo-Controlled, Dose Escalation Study to Assess the Efficacy, Safety and Pharmacokinetics of Voclosporin in Adolescents with Lupus Nephritis | |||||||||||||
Medical condition: Lupus Nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Ongoing) FR (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-001645-41 | Sponsor Protocol Number: JAK115919 | Start Date*: 2013-02-19 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Limited | |||||||||||||
Full Title: An adaptive Phase II study to evaluate the efficacy, pharmacodynamics, safety and tolerability of GSK2586184 in patients with active systemic lupus erythematosus. | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) HU (Prematurely Ended) SE (Prematurely Ended) ES (Prematurely Ended) GR (Completed) EE (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004296-36 | Sponsor Protocol Number: CD-IA-MEDI-546-1013 | Start Date*: 2012-08-29 | |||||||||||
Sponsor Name:MedImmune, LLC, | |||||||||||||
Full Title: A Phase 2, Randomized Study to Evaluate the Efficacy and Safety of MEDI-546 in Subjects with Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Completed) HU (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-001203-79 | Sponsor Protocol Number: IM011021 | Start Date*: 2017-12-04 | |||||||||||
Sponsor Name:Bristol-Myers Squibb international Corporation | |||||||||||||
Full Title: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of BMS-986165 in Subjects with Systemic Lupus Erythematosus | |||||||||||||
Medical condition: Systemic Lupus Erythematosus | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Completed) PL (Completed) DE (Completed) ES (Ongoing) RO (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004034-42 | Sponsor Protocol Number: CA41705 | Start Date*: 2020-08-31 | |||||||||||
Sponsor Name:F. Hoffmann-La Roche Ltd | |||||||||||||
Full Title: A PHASE III, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS | |||||||||||||
Medical condition: lupus nephritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) GB (GB - no longer in EU/EEA) IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2016-002950-19 | Sponsor Protocol Number: MS200527-0018 | Start Date*: 2017-04-27 | |||||||||||
Sponsor Name:Merck KGaA | |||||||||||||
Full Title: A Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Study To Evaluate the Safety and Efficacy of M2951 in Subjects with Systemic Lupus Erythematosus (SLE) | |||||||||||||
Medical condition: Systemic Lupus Erythematosus (SLE) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BG (Prematurely Ended) PL (Completed) DE (Completed) RO (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
